Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases

此次收购通过引入针对皮肤病、呼吸系统疾病及其他炎症和免疫性疾病的多元化资产，进一步夯实了艾伯维强大的免疫学产品管线。

Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis

Apogee的核心资产zumilokibart是一种靶向IL-13的长效单克隆抗体，正处于后期开发阶段，用于治疗特应性皮炎患者。

Apogee's pipeline also includes APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), in development for asthma

Apogee 的研发管线还包括 APG273，这是一种潜在的同类最优长效组合疗法，靶向 IL-13 和胸腺基质淋巴细胞生成素（TSLP），目前正在开发用于哮喘治疗。

AbbVie reaffirms previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88

艾伯维重申此前发布的2026年全年调整后稀释每股收益指引区间为13.87美元至14.07美元；重申此前发布的第三季度调整后稀释每股收益指引区间为3.84美元至3.88美元

NORTH CHICAGO, Ill.

伊利诺伊州，北芝加哥

,

，

Sept. 3, 2026

2026年9月3日

/PRNewswire/ -- AbbVie (NYSE:

/美通社/ -- 艾伯维（纽约证券交易所：

ABBV

艾伯维

) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ:

）今日宣布，已完成对 Apogee Therapeutics, Inc.（纳斯达克股票代码：

APGE

亚太地理信息工程

). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.

随着收购完成，Apogee 现已成为艾伯维（AbbVie）的一部分。根据协议条款，Apogee 股东每股获得 135.11 美元现金，总股权价值约为 109 亿美元。

'The completion of the Apogee acquisition is an important step in further strengthening AbbVie's leadership in immunology and advancing our long-term growth strategy,' said Robert A. Michael, chairman and chief executive officer, AbbVie. 'By combining Apogee's innovative science with AbbVie's proven development, regulatory and commercial capabilities, we aim to accelerate these programs and bring promising new treatment options to patients living with serious inflammatory and immunological diseases.

艾伯维董事长兼首席执行官罗伯特·A·迈克尔表示：“完成对Apogee的收购是进一步巩固艾伯维在免疫学领域领导地位、推进我们长期增长战略的重要一步。通过将Apogee的创新科学与艾伯维经过验证的开发、监管和商业化能力相结合，我们旨在加速这些项目的进展，为患有严重炎症性和免疫性疾病的患者带来有前景的新治疗选择。”

We are excited to welcome the talented Apogee team to AbbVie and build on their important work.'.

我们很高兴欢迎才华横溢的Apogee团队加入艾伯维，并在他们的重要工作基础上继续发展。

Apogee's pipeline includes novel antibodies targeting multiple validated inflammatory pathways in large immunology and inflammation markets, including atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD).

Apogee的在研管线包括多种新型抗体，靶向大型免疫学与炎症市场（如特应性皮炎[AD]、哮喘和慢性阻塞性肺疾病[COPD]）中多个经验证的炎症通路。

Zumilokibart targets IL-13, a critical cytokine in type 2 inflammation, and a central driver of inflammatory diseases like AD and asthma. Specifically in AD, a majority of patients do not achieve simultaneous itch and skin improvement which represents an opportunity for the development of novel treatments that not only provide better skin clearance and itch resolution but also improve convenience with less frequent dosing.

Zumilokibart 靶向白细胞介素-13（IL-13），这是2型炎症中的关键细胞因子，也是特应性皮炎（AD）和哮喘等炎症性疾病的核心驱动因素。特别是在特应性皮炎中，大多数患者未能同时实现瘙痒缓解和皮肤改善，这为开发新型疗法提供了机会，这些疗法不仅能更好地清除皮损和缓解瘙痒，还能通过减少给药频率提高用药便利性。

In its Phase 2 clinical trial, zumilokibart attained clinically significant results, with approximately two-thirds of patients on treatment achieving significant skin clearance at 16 weeks, along with notable improvements in itch reduction and overall disease control. These findings support its potential best-in-category profile, including strong efficacy and convenient dosing, in patients with AD.

在二期临床试验中，zumilokibart 取得了具有临床意义的结果：治疗16周时，约三分之二的接受治疗患者实现了显著的皮肤清除，同时瘙痒减轻和整体疾病控制方面也观察到明显改善。这些发现支持其在特应性皮炎（AD）患者中具备同类最佳潜力，包括疗效强劲和给药便捷。

Longer-term data from the same trial also support maintenance regimens of either quarterly or twice a year dosing. The safety profile of zumilokibart is favorable and consistent with other medicines in its class, and the molecule has the potential to be evaluated in several additional inflammatory indications..

来自同一试验的长期数据也支持每季度或每半年给药一次的维持治疗方案。Zumilokibart 的安全性良好，与其同类药物一致，并且该分子有望在多种其他炎症性适应症中进行评估。

Beyond zumilokibart, Apogee has built a broader pipeline of novel antibodies targeting multiple validated inflammatory pathways. APG273 combines zumilokibart with APG333, an antibody that blocks thymic stromal lymphopoietin (TSLP), a signaling protein that acts as an early trigger of inflammation in the lungs.

除zumilokibart外，Apogee还构建了更广泛的新型抗体研发管线，靶向多个经验证的炎症通路。APG273将zumilokibart与APG333联合使用，后者是一种阻断胸腺基质淋巴细胞生成素（TSLP）的抗体；TSLP是一种信号蛋白，可作为肺部炎症的早期触发因子。

Phase 1 data showed that APG333 has a long half-life and was able to suppress relevant type 2 inflammatory markers for up to six months after dosing. The Phase 1 data with APG333 and positive interim results from a Phase 1b study of zumilokibart in asthma, support the potential of the APG273 combination with quarterly or twice-yearly injections in asthma..

一期数据显示，APG333具有长半衰期，并且在给药后能够抑制相关的2型炎症标志物长达六个月。APG333的一期数据以及zumilokibart在哮喘治疗中的一项1b期研究的积极中期结果，支持了APG273联合疗法在哮喘治疗中每季度或每半年注射一次的潜力。

For additional background on the acquisition, please read the announcement press release

如需了解此次收购的更多背景信息，请阅读新闻稿公告。

here

这里

and view AbbVie's investor presentation

并查看艾伯维的投资者演示文稿

here

这里

.

。

Financial Terms

财务条款

AbbVie has acquired all outstanding Apogee common stock for $135.11 per share in cash, for a total equity value of approximately $10.9 billion. Apogee's common stock ceased trading on the NASDAQ stock exchange prior to market open on Sept. 3, 2026. AbbVie expects its acquisition of Apogee to negatively impact adjusted diluted earnings per share (EPS) by $0.14 in 2026 (partial year) and approximately $0.46 in 2027, with accretion beginning in 2032..

艾伯维已以每股135.11美元的现金价格收购Apogee全部流通普通股，总股权价值约为109亿美元。Apogee的普通股于2026年9月3日市场开盘前在纳斯达克证券交易所停止交易。艾伯维预计，此次收购将使2026年（部分年度）的调整后稀释每股收益（EPS）减少0.14美元，2027年减少约0.46美元，并从2032年开始产生增厚效应。

Full-year 2026 Outlook

2026年全年展望

AbbVie is reaffirming its previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07. This guidance includes a $0.14 per share dilutive impact related to the completed Apogee acquisition. AbbVie's 2026 adjusted diluted EPS guidance includes an unfavorable impact of $0.58 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter.

艾伯维重申其此前发布的2026年全年调整后稀释每股收益指引区间，为13.87美元至14.07美元。该指引包含与已完成的Apogee收购相关的每股0.14美元的稀释性影响。艾伯维2026年调整后稀释每股收益指引还包含一项不利因素，即截至第二季度累计发生的与收购获得的在研无形资产（IPR&D）及里程碑费用相关的每股0.58美元的影响。

The company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the second quarter of 2026, as both cannot be reliably forecasted..

公司2026年调整后稀释每股收益指引不包括任何来自收购的在研无形资产及可能在2026年第二季度之后产生的里程碑付款的影响，因为这两者均无法可靠预测。

AbbVie is reaffirming its previously issued 2026 third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88. AbbVie's 2026 third-quarter adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred in the quarter, as both cannot be reliably forecasted..

艾伯维重申其此前发布的2026年第三季度调整后稀释每股收益指引区间为3.84美元至3.88美元。艾伯维2026年第三季度的调整后稀释每股收益指引未包含因收购在研无形资产（IPR&D）及可能在当季产生的里程碑付款所带来的任何影响，因为这两项均无法可靠预测。

About

关于

AbbVie

艾伯维

in Immunology

免疫学

AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines.

艾伯维不懈追求重新定义免疫介导疾病患者的护理标准，旨在帮助他们摆脱疾病限制，享受自由生活。二十多年来，艾伯维凭借突破性的科学成果和值得信赖的药物，引领并塑造了免疫学领域的发展。

Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease..

依托在胃肠病学、风湿病学、皮肤病学以及其他存在高度未满足需求领域的深厚专业积累，我们持续投入于构建广泛且差异化的产品管线——涵盖创新疗法模式、新颖作用机制以及旨在攻克免疫介导疾病复杂生物学基础的下一代方法。

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 19 immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines.

如今，全球有超过100万患者正在接受艾伯维的免疫学药物治疗。这些药物已在175多个国家获批，用于治疗影响成人和儿童群体的19种免疫介导性疾病。在致力于巩固我们的传承并推动新一轮创新的同时，我们仍然专注于为患者带来有意义的进展，并扩大药物的可及性。

For more information, please visit .

更多信息，请访问。

www.abbvie.com/immunology

www.abbvie.com/immunology

.

。

About AbbVie

关于艾伯维

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio.

艾伯维的使命是发现并提供创新药物和解决方案，以解决当今严重的健康问题，并应对未来的医学挑战。我们致力于在免疫学、神经科学和肿瘤学等几个关键治疗领域，以及我们的艾尔建美学产品组合中的产品和服务方面，对人们的生活产生非凡的影响。

For more information about AbbVie, please visit us at .

有关艾伯维的更多信息，请访问我们的网站。

www.abbvie.com

www.abbvie.com

. Follow @abbvie on

在社交媒体上关注 @abbvie

LinkedIn,

领英，

Facebook

脸书

,

，

Instagram

Instagram

,

，

X

X

and

和

YouTube.

YouTube

Forward-Looking Statements

前瞻性陈述

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions and uses of future or conditional verbs generally identify forward-looking statements.

本新闻稿中的某些陈述属于或可能被视为1995年《私人证券诉讼改革法案》意义上的前瞻性陈述。“相信”、“预期”、“预计”、“预测”等词语及类似表述，以及将来时或条件式动词的使用，通常用于识别前瞻性陈述。

Statements in this news release that are forward-looking may include, but are not limited to, statements regarding AbbVie's 2026 full-year and third-quarter adjusted diluted EPS guidance, the anticipated benefits of AbbVie's completed acquisition of Apogee and AbbVie's ability to successfully integrate Apogee's operations, employees and pipeline; the expected impact of the acquisition on AbbVie's adjusted diluted earnings per share; and the anticipated development, regulatory progress and commercial potential of Apogee's pipeline assets.

本新闻稿中的前瞻性陈述可能包括但不限于以下内容：关于艾伯维（AbbVie）2026年全年及第三季度调整后稀释每股收益指引的陈述；关于艾伯维已完成对Apogee收购的预期收益，以及艾伯维成功整合Apogee运营、员工和产品管线的能力的陈述；关于该收购对艾伯维调整后稀释每股收益预期影响的陈述；以及关于Apogee管线资产的开发前景、监管进展和商业潜力的预期陈述。

AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: the amount and timing of acquired IPR&D and milestones expense; the risk that the anticipated benefits and synergies of the Apogee acquisition may not be realized, or may take longer to realize than expected; risks and costs related to integrating Apogee's business, employees and pipeline into AbbVie, including the possibility that such integration may be more difficult, time-consuming or costly than anticipated; the risk that acquired in-process research and development assets, including zumilokibart (APG777) and APG273, may not demonstrate the anticipated success, safety or efficacy in ongoing or future clinical trials, and that positive interim .

艾伯维提醒，这些前瞻性陈述受各种风险和不确定性的影响，可能导致实际结果与前瞻性陈述中明示或暗示的结果存在重大差异。此类风险和不确定性包括但不限于：收购的正在进行的研究与开发（IPR&D）及里程碑费用的金额和时间；Apogee 收购案预期的协同效应和收益可能无法实现，或实现时间长于预期的风险；将 Apogee 的业务、员工和产品管线整合到艾伯维相关的风险和成本，包括此类整合可能比预期更困难、更耗时或成本更高的可能性；所收购的正在进行的研究与开发资产（包括 zumilokibart（APG777）和 APG273）可能在当前或未来的临床试验中无法展现出预期的成功、安全性或疗效的风险，以及积极的 interim .

Media:

媒体：

Catherine Langel

凯瑟琳·兰格尔

[email protected]

[email protected]

Investors:

投资者：

Liz Shea

莉兹·谢伊

[email protected]

[email protected]

SOURCE AbbVie

来源：艾伯维

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示